Quantitative Analysis of Galectin-3 Expression in Benign and Malignant Thyroid Nodules

Overview

Journal Acta Clin Croat

Specialty General Medicine

Date 2021 Jul 5

PMID 34219881

Authors

Ivan Samija

Neven Matesa

Sanja Tadinac

Tomislav Jukic

Affiliations

Soon will be listed here.

Abstract

In this study, galectin-3 was analyzed as a potential marker for preoperative detection of malignant thyroid lesions. Galectin-3 expression was analyzed by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) in preoperative thyroid fine-needle aspirates from 245 patients with thyroid nodules. Out of 245 samples, 238 were adequate for analysis by RT-PCR. Galectin-3 was positive in 34 (89.5%) of 38 papillary carcinomas, 3 (89.5%) of 4 follicular carcinomas, 17 (53.1%) of 32 follicular adenomas, 2 (33.3%) of 6 Hurthle cell adenoma, 11 (28.2%) of 39 Hashimoto thyroiditis, and 69 (57.9%) of 119 nodular goiter samples. Galectin-3 showed specificity of 49.5%, sensitivity of 88.1%, positive predictive value of 27.2%, and negative predictive value of 95.1% as a marker for detection of malignant thyroid nodules. Owing to the relatively low positive predictive value due to the relatively high false positive rate, the clinical value of galectin-3 analyzed by quantitative real-time RT-PCR as a marker for preoperative detection of malignant thyroid lesions is limited.

References

Pineda P, Rojas P, Liberman C, Moyano L, Goecke I . [Detection of malignancy markers in thyroid nodules by reverse transcriptase polymerase chain reaction (RT-PCR)]. Rev Med Chil. 2003; 131(9):965-72. View

Gal A, Carnwath J, Dinnyes A, Herrmann D, Niemann H, Wrenzycki C . Comparison of real-time polymerase chain reaction and end-point polymerase chain reaction for the analysis of gene expression in preimplantation embryos. Reprod Fertil Dev. 2006; 18(3):365-71. DOI: 10.1071/rd05012. View

Sorrenti S, Trimboli P, Catania A, Ulisse S, De Antoni E, DArmiento M . Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm. Thyroid. 2009; 19(4):355-60. DOI: 10.1089/thy.2008.0338. View

Gasbarri A, Martegani M, Del Prete F, Lucante T, Natali P, Bartolazzi A . Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol. 1999; 17(11):3494-502. DOI: 10.1200/JCO.1999.17.11.3494. View

Matesa N, Samija I, Kusic Z . Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions. Cytopathology. 2007; 18(2):112-6. DOI: 10.1111/j.1365-2303.2006.00407.x. View

Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A . Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001; 357(9269):1644-50. DOI: 10.1016/s0140-6736(00)04817-0. View

Aratake Y, Umeki K, Kiyoyama K, Hinoura Y, Sato S, Ohno A . Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol. 2002; 26(6):366-72. DOI: 10.1002/dc.10111. View

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

Carpi A, Nicolini A, Gross M, Fig L, Shapiro B, Fanti S . Controversies in diagnostic approaches to the indeterminate follicular thyroid nodule. Biomed Pharmacother. 2005; 59(9):517-20. DOI: 10.1016/j.biopha.2005.04.003. View

10.

Kim E, Nam-Goong I, Gong G, Hong S, Kim W, Shong Y . Postoperative findings and risk for malignancy in thyroid nodules with cytological diagnosis of the so-called "follicular neoplasm". Korean J Intern Med. 2003; 18(2):94-7. PMC: 4531614. DOI: 10.3904/kjim.2003.18.2.94. View

11.

Rossi E, Pantanowitz L, Faquin W . The Role of Molecular Testing for the Indeterminate Thyroid FNA. Genes (Basel). 2019; 10(10). PMC: 6826845. DOI: 10.3390/genes10100736. View

12.

Samija I, Matesa N, Lukac J, Kusic Z . Galectin-3 and CD44v6 as markers for preoperative diagnosis of thyroid cancer by RT-PCR. Diagn Mol Pathol. 2011; 20(4):233-41. DOI: 10.1097/PDM.0b013e31821a59f1. View

13.

Asari R, Niederle B, Scheuba C, Riss P, Koperek O, Kaserer K . Indeterminate thyroid nodules: a challenge for the surgical strategy. Surgery. 2010; 148(3):516-25. DOI: 10.1016/j.surg.2010.01.020. View

14.

Sanabria A, Carvalho A, de Andrade V, Rodrigo J, Vartanian J, Rinaldo A . Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular neoplasm"? A critical appraisal of the evidence. Head Neck. 2007; 29(11):1046-54. DOI: 10.1002/hed.20642. View

15.

Chiu C, Strugnell S, Griffith O, Jones S, Gown A, Walker B . Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol. 2010; 176(5):2067-81. PMC: 2861072. DOI: 10.2353/ajpath.2010.090353. View

16.

Wang L, Guo X . Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression. Biomed Pharmacother. 2016; 78:165-171. DOI: 10.1016/j.biopha.2016.01.014. View

17.

Baloch Z, LiVolsi V . Fine-needle aspiration of thyroid nodules: past, present, and future. Endocr Pract. 2004; 10(3):234-41. DOI: 10.4158/EP.10.3.234. View

18.

Martins L, Matsuo S, Ebina K, Kulcsar M, Friguglietti C, Kimura E . Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002; 87(10):4806-10. DOI: 10.1210/jc.2002-020094. View

19.

Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J . Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol. 2004; 18(4):541-6. DOI: 10.1038/modpathol.3800321. View

20.

Carpi A, Rossi G, Di Coscio G, Iervasi G, Nicolini A, Carpi F . Galectin-3 detection on large-needle aspiration biopsy improves preoperative selection of thyroid nodules: a prospective cohort study. Ann Med. 2009; 42(1):70-8. DOI: 10.3109/07853890903439778. View